Published in Biomed Res Int on October 18, 2015
Clinical association of baseline levels of conjugated dienes in low-density lipoprotein and nitric oxide with aggressive B-cell non-Hodgkin lymphoma and their relationship with immunoglobulins and Th1-to-Th2 ratio. J Blood Med (2016) 0.75
PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line. Oncotarget (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell (2005) 17.81
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 8.56
Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol (2009) 7.96
Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ (2007) 4.12
Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol (2009) 2.61
Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol Sci (2003) 2.35
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia (2006) 2.28
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res (2005) 1.50
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res (2010) 1.46
Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med (2013) 1.46
G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest (2002) 1.41
PI3K signaling in glioma--animal models and therapeutic challenges. Brain Pathol (2009) 1.36
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther (2012) 1.26
Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev (2013) 1.25
Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal (2014) 1.13
Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer (2011) 1.10
Targeting autophagy to fight hematopoietic malignancies. Cell Cycle (2010) 1.06
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev (2012) 1.03
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia (2013) 1.00
The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer (2012) 0.96
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget (2014) 0.96
Nuclear PI3K signaling in cell growth and tumorigenesis. Front Cell Dev Biol (2015) 0.96
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget (2010) 0.93
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res (2011) 0.93
Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia. Oncotarget (2014) 0.91
Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer (2013) 0.89
Whole cell microtubule analysis by flow cytometry. Anal Biochem (2011) 0.84
Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy (2012) 0.83
Targeting oncogenic and epigenetic survival pathways in lymphoma. Leuk Lymphoma (2013) 0.81
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opin Investig Drugs (2012) 0.81
Role of GLUT1 in regulation of reactive oxygen species. Redox Biol (2014) 0.80
Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma (2010) 0.79
Advances in subunits of PI3K class I in cancer. Pathology (2014) 0.78
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leuk Res (2015) 0.78